Stockscreener 앱 받기
88.08
5.18%
4.34
전일 마감가:
$83.74
열려 있는:
$88.39
하루 거래량:
15.00M
Relative Volume:
1.84
시가총액:
$390.99B
수익:
$42.09B
순이익/손실:
$14.65B
주가수익비율:
26.83
EPS:
3.2833
순현금흐름:
$10.11B
1주 성능:
+13.11%
1개월 성능:
+8.70%
6개월 성능:
-34.74%
1년 성능:
-27.16%
1일 변동 폭
$85.74
$89.23
1주일 범위
$81.06
$89.23
52주 변동 폭
$77.82
$148.15
노보 노디스크 Stock (NVO) Company Profile
NVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Are Investors Inclined To Sell Their Novo Nordisk ADR (NYSE: NVO) Holdings? - Stocks Register
The Attractiveness of Investing In Novo Nordisk ADR (NVO) is Growing - Knox Daily
Ero Copper Corp (ERO) gets rating Initiated from Goldman - Knox Daily
Itau Unibanco Holding S.A. ADR (ITUB) Stock Records -5.92% Quarterly Movement - The News Heater
Novo Nordisk ADR (NVO) Shares Decline Despite Market Challenges - The News Heater
A Stock Analysis Of Novo Nordisk ADR’s (NVO) - Stocks Register
Examining Novo Nordisk ADR (NVO) more closely is necessary - US Post News
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up - MSN
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth - Morningstar
Novo Nordisk ADR [NVO] Is Currently -0.04 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Novo Nordisk Stock Rises After Earnings. It Expects Good News From the FDA. - Barron's
Novo Nordisk Shares Surge on Strong Sales of Wegovy, Despite Slight Earnings Miss – market - HPBL
Novo Nordisk Stock Up After Earnings. Weight-Loss Drugmaker Sees Slower Growth. - Barron's
Novo Nordisk ADR earnings beat by $5.46, revenue topped estimates - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/SNVO - cnhinews.com
Novo Nordisk ADR (NVO) Stock: A Look at the Analyst Recommendations - The News Heater
Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading Weight Loss in Small Trial - Morningstar
2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs - Morningstar
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.60%
자본화:
|
볼륨(24시간):